28 April 2017
News and Views
Links and Services
This week's publication of the New England Journal of Medicine evaluates the use of ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
High rates of sustained virologic response were observed among patients with hepatitis C virus (H
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors